ARIA/CAA Prediction Model
Risk prediction for Amyloid-Related Imaging Abnormalities / Cerebral Amyloid Angiopathy
Key Facts
About Pre Diagnostics
Pre Diagnostics is an early-stage, private diagnostics company developing a proprietary platform for the early detection of neurodegenerative diseases by analyzing biomarkers inside blood cells (monocytes), rather than in the bloodstream. Its lead program targets Alzheimer's disease (AD) by measuring the dynamic clearance of beta-amyloid, positioning it as a potential tool for pre-symptomatic diagnosis. The company is pre-revenue and research-focused, having recently secured significant non-dilutive funding through a €7.7 million EU Horizon grant to advance its FluiDx-AD project. Its innovative approach differentiates it from conventional plasma-based biomarker tests.
View full company profile